-
1
-
-
34147174870
-
Venous thromboembolism and cancer
-
Bergqvist D, et al. Venous thromboembolism and cancer. Curr Probl Surg 2007; 44: 157-216.
-
(2007)
Curr Probl Surg
, vol.44
, pp. 157-216
-
-
Bergqvist, D.1
-
3
-
-
19944369810
-
Cancer and venous thromboembolism
-
Prandoni P, et al. Cancer and venous thromboembolism. Lancet Oncol 2005; 6: 401-410.
-
(2005)
Lancet Oncol
, vol.6
, pp. 401-410
-
-
Prandoni, P.1
-
4
-
-
36049000503
-
Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients
-
DOI 10.1002/cncr.23062
-
Khorana AA, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 110: 2339-2346. (Pubitemid 350100757)
-
(2007)
Cancer
, vol.110
, Issue.10
, pp. 2339-2346
-
-
Khorana, A.A.1
Francis, C.W.2
Culakova, E.3
Kuderer, N.M.4
Lyman, G.H.5
-
5
-
-
36849070772
-
American Society of Clinical Oncology Guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer
-
DOI 10.1200/JCO.2007.14.1283
-
Lyman GH, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505. (Pubitemid 350232226)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.34
, pp. 5490-5505
-
-
Lyman, G.H.1
Khorana, A.A.2
Falanga, A.3
Clarke-Pearson, D.4
Flowers, C.5
Jahanzeb, M.6
Kakkar, A.7
Kuderer, N.M.8
Levine, M.N.9
Liebman, H.10
Mendelson, D.11
Raskob, G.12
Somerfield, M.R.13
Thodiyil, P.14
Trent, D.15
Francis, C.W.16
-
6
-
-
70449496720
-
-
V.2
-
National Cancer Comprehensive Network Clinical Practise Guidelines in Oncology. Venous Thromboembolic Disease.V.2.2008. http://www.nccn.org/profes sionals/physician-gls/PDF/vte.pdf
-
(2008)
Venous Thromboembolic Disease
-
-
-
7
-
-
33748787140
-
Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM)
-
DOI 10.1016/j.critrevonc.2006.05.001, PII S1040842806001041
-
Mandala M, et al. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol 2006; 59: 194-204. (Pubitemid 44403960)
-
(2006)
Critical Reviews in Oncology/Hematology
, vol.59
, Issue.3
, pp. 194-204
-
-
Mandala, M.1
Falanga, A.2
Piccioli, A.3
Prandoni, P.4
Pogliani, E.M.5
Labianca, R.6
Barni, S.7
-
8
-
-
4644288189
-
Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
-
Geerts WH, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 338S-400S.
-
(2004)
Chest
, vol.126
, Issue.3 SUPPL.
-
-
Geerts, W.H.1
-
9
-
-
0035655428
-
The effects of vitamin K-antagonists on survival of patients with malignancy: A systematic analysis
-
Smorenburg SM, et al. The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost 2001; 86: 1586-1587.
-
(2001)
Thromb Haemost
, vol.86
, pp. 1586-1587
-
-
Smorenburg, S.M.1
-
10
-
-
33847291915
-
Mechanisms of heparin induced anti-cancer activity in experimental cancer models
-
Niers TM, et al. Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol 2007; 61: 195-207.
-
(2007)
Crit Rev Oncol Hematol
, vol.61
, pp. 195-207
-
-
Niers, T.M.1
-
11
-
-
36049045718
-
Cancer, thrombosis and heparin-induced thrombocytopenia
-
Prandoni P, et al. Cancer, thrombosis and heparin-induced thrombocytopenia. Thromb Res 2007; 120 (Suppl 2): S137-S140.
-
(2007)
Thromb Res
, vol.120
, Issue.SUPPL. 2
-
-
Prandoni, P.1
-
12
-
-
0035876016
-
Molecular basis for the relationship between thrombosis and cancer
-
DOI 10.1016/S0049-3848(01)00285-7, PII S0049384801002857
-
Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001; 102: V215-V224. (Pubitemid 32539212)
-
(2001)
Thrombosis Research
, vol.102
, Issue.6
-
-
Rickles, F.R.1
Falanga, A.2
-
13
-
-
0036185995
-
Anticoagulants in thrombosis and cancer: The missing link
-
DOI 10.1055/s-2002-20559
-
Mousa SA. Anticoagulants in thrombosis and cancer: the missing link. Semin Thromb Hemost 2002; 28: 45-52. (Pubitemid 34194872)
-
(2002)
Seminars in Thrombosis and Hemostasis
, vol.28
, Issue.1
, pp. 45-52
-
-
Mousa, S.A.1
-
14
-
-
36348957925
-
Heparin in tumor progression and metastatic dissemination
-
DOI 10.1055/s-2007-991536
-
Falanga A, Marchetti M. Heparin in tumor progression and metastatic dissemination. Semin Thromb Hemost 2007; 33: 688-694. (Pubitemid 350157013)
-
(2007)
Seminars in Thrombosis and Hemostasis
, vol.33
, Issue.7
, pp. 688-694
-
-
Falanga, A.1
Marchetti, M.2
-
15
-
-
34147125963
-
Cancer-associated thrombosis
-
Zwicker JI, et al. Cancer-associated thrombosis. Crit Rev Oncol Hematol 2007; 62: 126-136.
-
(2007)
Crit Rev Oncol Hematol
, vol.62
, pp. 126-136
-
-
Zwicker, J.I.1
-
16
-
-
1842830277
-
Cancer and thrombosis: Mechanisms and treatment
-
Deitcher SR. Cancer and thrombosis: mechanisms and treatment. J Thromb Thrombolysis 2003; 16: 21-31.
-
(2003)
J Thromb Thrombolysis
, vol.16
, pp. 21-31
-
-
Deitcher, S.R.1
-
17
-
-
0027302891
-
Guidelines for clotting studies in cancer patients
-
For the Scientific and Standardization Committee of the Subcommittee on Haemostasis and Malignancy International Society of Thrombosis and Haemostasis
-
Falanga A, et al. Guidelines for clotting studies in cancer patients. For the Scientific and Standardization Committee of the Subcommittee on Haemostasis and Malignancy International Society of Thrombosis and Haemostasis. Thromb Haemost 1993; 70: 540-542.
-
(1993)
Thromb Haemost
, vol.70
, pp. 540-542
-
-
Falanga, A.1
-
18
-
-
1842828919
-
Tissue factor pathway inhibitor in thrombosis and beyond
-
Mousa SA, et al. Tissue factor pathway inhibitor in thrombosis and beyond. Methods Mol Med 2004; 93: 133-155.
-
(2004)
Methods Mol Med
, vol.93
, pp. 133-155
-
-
Mousa, S.A.1
-
19
-
-
12344275879
-
The heparins and cancer: Review of clinical trials and biological properties
-
DOI 10.1191/1358863x04vm566ra
-
Castelli R, et al. The heparins and cancer: review of clinical trials and biological properties. Vasc Med 2004; 9: 205-213. (Pubitemid 40124086)
-
(2004)
Vascular Medicine
, vol.9
, Issue.3
, pp. 205-213
-
-
Castelli, R.1
Porro, F.2
Tarsia, P.3
-
20
-
-
40049088602
-
The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages
-
DOI 10.1016/j.critrevonc.2007.07.004, PII S104084280700162X
-
Allavena P, et al. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008; 66: 1-9. (Pubitemid 351324128)
-
(2008)
Critical Reviews in Oncology/Hematology
, vol.66
, Issue.1
, pp. 1-9
-
-
Allavena, P.1
Sica, A.2
Solinas, G.3
Porta, C.4
Mantovani, A.5
-
21
-
-
48749128011
-
Tissue factor and protease-activated receptor signaling in cancer
-
Schaffner F, Ruf W. Tissue factor and protease-activated receptor signaling in cancer. Semin Thromb Hemost 2008; 34: 147-153.
-
(2008)
Semin Thromb Hemost
, vol.34
, pp. 147-153
-
-
Schaffner, F.1
Ruf, W.2
-
22
-
-
0030857363
-
Tissue factor in health and disease
-
Semeraro N, Colucci M. Tissue factor in health and disease. Thromb Haemost 1997; 78: 759-764.
-
(1997)
Thromb Haemost
, vol.78
, pp. 759-764
-
-
Semeraro, N.1
Colucci, M.2
-
23
-
-
0034672149
-
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera
-
Falanga A, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000; 96: 4261-4266.
-
(2000)
Blood
, vol.96
, pp. 4261-4266
-
-
Falanga, A.1
-
24
-
-
38549162640
-
Inflammation, inflammatory cells and angiogenesis: Decisions and indecisions
-
Noonan DM, et al. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev 2008; 27: 31-40.
-
(2008)
Cancer Metastasis Rev
, vol.27
, pp. 31-40
-
-
Noonan, D.M.1
-
25
-
-
0032610504
-
Heparin in inflammation: Potential therapeutic applications beyond anticoagulation
-
Tyrrell DJ, et al. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999; 46: 151-208.
-
(1999)
Adv Pharmacol
, vol.46
, pp. 151-208
-
-
Tyrrell, D.J.1
-
26
-
-
33748647001
-
Structural requirements of heparin and related molecules to exert a multitude of anti-inflammatory activities
-
Ludwig RJ, et al. Structural requirements of heparin and related molecules to exert a multitude of anti-inflammatory activities. Mini Rev Med Chem 2006; 6: 1009-1023.
-
(2006)
Mini Rev Med Chem
, vol.6
, pp. 1009-1023
-
-
Ludwig, R.J.1
-
27
-
-
36348974088
-
Inhibition of platelet function: Does it offer a chance of better cancer progression control?
-
Sierko E, Wojtukiewicz MZ. Inhibition of platelet function: does it offer a chance of better cancer progression control? Semin Thromb Hemost 2007; 33: 712-721.
-
(2007)
Semin Thromb Hemost
, vol.33
, pp. 712-721
-
-
Sierko, E.1
Wojtukiewicz, M.Z.2
-
28
-
-
36348929983
-
The role of tissue factor pathway inhibitor in tumor growth and metastasis
-
DOI 10.1055/s-2007-991531
-
Amirkhosravi A, et al. The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin Thromb Hemost 2007; 33: 643-652. (Pubitemid 350157007)
-
(2007)
Seminars in Thrombosis and Hemostasis
, vol.33
, Issue.7
, pp. 643-652
-
-
Amirkhosravi, A.1
Meyer, T.2
Amaya, M.3
Davila, M.4
Mousa, S.A.5
Robson, T.6
Francis, J.L.7
-
30
-
-
36349030324
-
Antiangiogenic antithrombin
-
O'Reilly MS. Antiangiogenic antithrombin. Semin Thromb Hemost 2007; 33: 660-666.
-
(2007)
Semin Thromb Hemost
, vol.33
, pp. 660-666
-
-
O'Reilly, M.S.1
-
31
-
-
36349025914
-
Protein C and its inhibitor in malignancy
-
Suzuki K, Hayashi T. Protein C and its inhibitor in malignancy. Semin Thromb Hemost 2007; 33: 667-672.
-
(2007)
Semin Thromb Hemost
, vol.33
, pp. 667-672
-
-
Suzuki, K.1
Hayashi, T.2
-
32
-
-
36348932861
-
The role of thrombomodulin in malignancy
-
Hanly AM, Winter DC. The role of thrombomodulin in malignancy. Semin Thromb Hemost 2007; 33: 673-679.
-
(2007)
Semin Thromb Hemost
, vol.33
, pp. 673-679
-
-
Hanly, A.M.1
Winter, D.C.2
-
33
-
-
36348999275
-
The role of hemostatic system inhibitors in malignancy
-
Wojtukiewicz MZ, et al. The role of hemostatic system inhibitors in malignancy. Semin Thromb Hemost 2007; 33: 621-642.
-
(2007)
Semin Thromb Hemost
, vol.33
, pp. 621-642
-
-
Wojtukiewicz, M.Z.1
-
34
-
-
0035109328
-
The complex effects of heparins on cancer progression and metastasis in experimental studies
-
Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001; 53: 93-105. (Pubitemid 32173109)
-
(2001)
Pharmacological Reviews
, vol.53
, Issue.1
, pp. 93-105
-
-
Smorenburg, S.M.1
Van Noorden, C.J.F.2
-
35
-
-
23844481864
-
Mechanisms of disease: The impact of antithrombotic therapy in cancer patients
-
DOI 10.1038/ncponc0225, PII N0225
-
Petralia GA, et al. Mechanisms of disease: the impact of antithrombotic therapy in cancer patients. Nat Clin Pract Oncol 2005; 2: 356-363. (Pubitemid 43118122)
-
(2005)
Nature Clinical Practice Oncology
, vol.2
, Issue.7
, pp. 356-363
-
-
Petralia, G.A.1
Lemoine, N.R.2
Kakkar, A.K.3
-
36
-
-
38049101163
-
Inhibition of tissue factor signaling suppresses tumor growth
-
Versteeg HH, et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood 2008; 111: 190-199.
-
(2008)
Blood
, vol.111
, pp. 190-199
-
-
Versteeg, H.H.1
-
37
-
-
33644830185
-
Low-molecular-weight heparins and angiogenesis
-
Norrby K. Low-molecular-weight heparins and angiogenesis. APMIS 2006; 114: 79-102.
-
(2006)
APMIS
, vol.114
, pp. 79-102
-
-
Norrby, K.1
-
38
-
-
34547094356
-
Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: Emerging links
-
Mousa SA. Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links. Semin Thromb Hemost 2007; 33: 524-533.
-
(2007)
Semin Thromb Hemost
, vol.33
, pp. 524-533
-
-
Mousa, S.A.1
-
39
-
-
2942563927
-
Antitumor and antimetastatic effect of warfarin and heparins
-
DOI 10.1016/j.biopha.2003.11.007, PII S0753332204000320
-
Bobek V, Kovarik J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 2004; 58: 213-219. (Pubitemid 38746746)
-
(2004)
Biomedicine and Pharmacotherapy
, vol.58
, Issue.4
, pp. 213-219
-
-
Bobek, V.1
Kovarik, J.2
-
40
-
-
33748750989
-
Recent findings for anti-metastatic potential of heparin [1]
-
DOI 10.1177/1076029606291422
-
Altundag K, et al. Recent findings for anti-metastatic potential of heparin. Clin Appl Thromb Hemost 2006; 12: 376-377. (Pubitemid 44400853)
-
(2006)
Clinical and Applied Thrombosis/Hemostasis
, vol.12
, Issue.3
, pp. 376-377
-
-
Altundag, K.1
Altundag, O.2
Atik, M.A.3
Boruban, C.4
Altundag, M.B.5
Turen, S.6
-
41
-
-
15244345079
-
The monomer-dimer equilibrium of stromal cell-derived factor-1 (CXCL 12) is altered by pH, phosphate, sulfate, and heparin
-
Veldkamp CT, et al. The monomer-dimer equilibrium of stromal cell-derived factor-1 (CXCL 12) is altered by pH, phosphate, sulfate, and heparin. Protein Sci 2005; 14: 1071-1081.
-
(2005)
Protein Sci
, vol.14
, pp. 1071-1081
-
-
Veldkamp, C.T.1
-
42
-
-
33947410027
-
Inhibition of CXCR4-mediated breast cancer metastasis: A potential role for heparinoids?
-
Harvey JR, et al. Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids? Clin Cancer Res 2007; 13: 1562-1570.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 1562-1570
-
-
Harvey, J.R.1
-
43
-
-
36048955098
-
Heparanase, heparin and the coagulation system in cancer progression
-
DOI 10.1016/S0049-3848(07)70139-1, PII S0049384807701391
-
Vlodavsky I, et al. Heparanase, heparin and the coagulation system in cancer progression. Thromb Res 2007; 120 (Suppl 2): S112-S120. (Pubitemid 350101779)
-
(2007)
Thrombosis Research
, vol.120
, Issue.SUPPL. 2
-
-
Vlodavsky, I.1
Ilan, N.2
Nadir, Y.3
Brenner, B.4
Katz, B.-Z.5
Naggi, A.6
Torri, G.7
Casu, B.8
Sasisekharan, R.9
-
44
-
-
34547126462
-
Antimetastatic activities of modified heparins: Selectin inhibition by heparin attenuates metastasis
-
Borsig L. Antimetastatic activities of modified heparins: selectin inhibition by heparin attenuates metastasis. Semin Thromb Hemost 2007; 33: 540-546.
-
(2007)
Semin Thromb Hemost
, vol.33
, pp. 540-546
-
-
Borsig, L.1
-
45
-
-
35948980396
-
P-selectin- And heparanase-dependent antimetastatic activity of non-anticoagulant heparins
-
DOI 10.1096/fj.07-8450com
-
Hostettler N, et al. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J 2007; 21: 3562-3572. (Pubitemid 350075146)
-
(2007)
FASEB Journal
, vol.21
, Issue.13
, pp. 3562-3572
-
-
Hostettler, N.1
Naggi, A.2
Torri, G.3
Ishai-Michaeli, R.4
Casu, B.5
Vlodavsky, I.6
Borsig, L.7
-
46
-
-
33645983628
-
Heparanase neutralizes the anticoagulation properties of heparin and low-molecularweight heparin
-
Nasser NJ, et al. Heparanase neutralizes the anticoagulation properties of heparin and low-molecularweight heparin. J Thromb Haemost 2006; 4: 560-565.
-
(2006)
J Thromb Haemost
, vol.4
, pp. 560-565
-
-
Nasser, N.J.1
-
47
-
-
43949084693
-
Heparin and low-molecular-weight heparin
-
Gray E, et al. Heparin and low-molecular-weight heparin. Thromb Haemost 2008; 99: 807-818.
-
(2008)
Thromb Haemost
, vol.99
, pp. 807-818
-
-
Gray, E.1
-
48
-
-
0032955744
-
Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials
-
Gould MK, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800-809.
-
(1999)
Ann Intern Med
, vol.130
, pp. 800-809
-
-
Gould, M.K.1
-
49
-
-
0029925784
-
Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
-
DOI 10.1016/S0002-9343(97)89484-3
-
Siragusa S, et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a metaanalysis. Am J Med 1996; 100: 269-277. (Pubitemid 26111623)
-
(1996)
American Journal of Medicine
, vol.100
, Issue.3
, pp. 269-277
-
-
Siragusa, S.1
Cosmi, B.2
Piovella, F.3
Hirsh, J.4
Ginsberg, J.S.5
-
50
-
-
0034707685
-
A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency
-
Dolovich LR, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000; 160: 181-188.
-
(2000)
Arch Intern Med
, vol.160
, pp. 181-188
-
-
Dolovich, L.R.1
-
51
-
-
35448956532
-
No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular- weight heparin or unfractionated heparin: A metaanalysis
-
Morris TA, et al. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular- weight heparin or unfractionated heparin: a metaanalysis. Chest 2007; 132: 1131-1139.
-
(2007)
Chest
, vol.132
, pp. 1131-1139
-
-
Morris, T.A.1
-
53
-
-
34548169044
-
A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: Impact on survival and bleeding complications
-
Kuderer NM, et al. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 2007; 110: 1149-1161.
-
(2007)
Cancer
, vol.110
, pp. 1149-1161
-
-
Kuderer, N.M.1
-
54
-
-
34248525326
-
The effect of anticoagulants on cancer risk and survival: Systematic review
-
DOI 10.1016/j.ctrv.2007.02.004, PII S0305737207000357
-
Tagalakis V, et al. The effect of anticoagulants on cancer risk and survival: systematic review. Cancer Treat Rev 2007; 33: 358-368. (Pubitemid 46760529)
-
(2007)
Cancer Treatment Reviews
, vol.33
, Issue.4
, pp. 358-368
-
-
Tagalakis, V.1
Blostein, M.2
Robinson-Cohen, C.3
Kahn, S.R.4
-
55
-
-
38649098255
-
Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation
-
CD006652
-
Akl EA, et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev 2007; 3: CD006652.
-
(2007)
Cochrane Database Syst Rev
, vol.3
-
-
Akl, E.A.1
-
56
-
-
17144385138
-
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism
-
DOI 10.1200/JCO.2005.03.133
-
Lee AY, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123-2129. (Pubitemid 46218703)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.10
, pp. 2123-2129
-
-
Lee, A.Y.Y.1
Rickles, F.R.2
Julian, J.A.3
Gent, M.4
Baker, R.I.5
Bowden, C.6
Kakkar, A.K.7
Prins, M.8
Levine, M.N.9
-
57
-
-
3042704507
-
Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS)
-
Kakkar AK, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944-1948.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1944-1948
-
-
Kakkar, A.K.1
-
58
-
-
20244376337
-
The effect of low molecular weight heparin on survival in patients with advanced malignancy
-
DOI 10.1200/JCO.2005.03.134
-
Klerk CP, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 2130-2135. (Pubitemid 46218704)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.10
, pp. 2130-2135
-
-
Klerk, C.P.W.1
Smorenburg, S.M.2
Otten, H.-M.3
Lensing, A.W.A.4
Prins, M.H.5
Piovella, F.6
Prandoni, P.7
Bos, M.M.E.M.8
Richel, D.J.9
Van Tienhoven, G.10
Buller, H.R.11
-
59
-
-
12844289104
-
A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer
-
DOI 10.1111/j.1538-7836.2004.00871.x
-
Altinbas M, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular- weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2: 1266-1271. (Pubitemid 40186120)
-
(2004)
Journal of Thrombosis and Haemostasis
, vol.2
, Issue.8
, pp. 1266-1271
-
-
Altinbas, M.1
Coskun, H.S.2
Er, O.3
Ozkan, M.4
Eser, B.5
Unal, A.6
Cetin, M.7
Soyuer, S.8
-
60
-
-
1842608584
-
Extending the role of antithrombotic agents: An example based on the low-molecular-weight heparin, tinzaparin
-
Hainer JW, et al. Extending the role of antithrombotic agents: an example based on the low-molecular-weight heparin, tinzaparin. Semin Thromb Hemost 2004; 30 (Suppl 1): 3-9.
-
(2004)
Semin Thromb Hemost
, vol.30
, Issue.SUPPL. 1
, pp. 3-9
-
-
Hainer, J.W.1
-
61
-
-
0025877941
-
Prevention of perioperative deep vein thrombosis in general surgery: A multicentre double blind study comparing two doses of Logiparin and standard heparin
-
H.B.P.M. Research Group
-
Liezorovicz A, et al. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. H.B.P.M. Research Group. Br J Surg 1991; 78: 412-416.
-
(1991)
Br J Surg
, vol.78
, pp. 412-416
-
-
Liezorovicz, A.1
-
62
-
-
0025976705
-
Prevention of thromboembolism in 190 hip arthroplasties. Comparison of LMW heparin and placebo
-
Lassen MR, et al. Prevention of thromboembolism in 190 hip arthroplasties. Comparison of LMW heparin and placebo. Acta Orthop Scand 1991; 62: 33-38.
-
(1991)
Acta Orthop Scand
, vol.62
, pp. 33-38
-
-
Lassen, M.R.1
-
63
-
-
0026576068
-
Subcutaneous low-molecularweight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis
-
Hull RD, et al. Subcutaneous low-molecularweight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-982.
-
(1992)
N Engl J Med
, vol.326
, pp. 975-982
-
-
Hull, R.D.1
-
64
-
-
8544273238
-
A comparison of low-molecular- weight heparin with unfractionated heparin for acute pulmonary embolism
-
The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire
-
Simonneau G, et al. A comparison of low-molecular- weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997; 337: 663-669.
-
(1997)
N Engl J Med
, vol.337
, pp. 663-669
-
-
Simonneau, G.1
-
65
-
-
0032892273
-
Prevention of deep vein thrombosis after hip replacement. Comparison between two low-molecular-weight heparins, tinzaparin and enoxaparin
-
Planes A, et al. Prevention of deep vein thrombosis after hip replacement - comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost 1999; 81: 22-25. (Pubitemid 29041643)
-
(1999)
Thrombosis and Haemostasis
, vol.81
, Issue.1
, pp. 22-25
-
-
Planes, A.1
Samama, M.M.2
Lensing, A.W.A.3
Buller, H.R.4
Barre, J.5
Vochelle, N.6
Beau, B.7
-
66
-
-
0027504813
-
A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation
-
DOI 10.1056/NEJM199311043291902
-
Hull R, et al. A comparison of subcutaneous lowmolecular- weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329: 1370-1376. (Pubitemid 23317346)
-
(1993)
New England Journal of Medicine
, vol.329
, Issue.19
, pp. 1370-1376
-
-
Hull, R.1
Raskob, G.2
Pineo, G.3
Rosenbloom, D.4
Evans, W.5
Mallory, T.6
Anquist, K.7
Smith, F.8
Hughes, G.9
Green, D.10
Elliott, C.G.11
Panju, A.12
Brant, R.13
-
67
-
-
10744223103
-
Home treatment of deep vein thrombosis. An out-patient treatment model with once-daily injection of low-molecular-weight heparin (tinzaparin) in 555 patients
-
Lapidus L, et al. Home treatment of deep vein thrombosis. An out-patient treatment model with once-daily injection of low-molecular-weight heparin (tinzaparin) in 555 patients. Pathophysiol Haemost Thromb 2002; 32: 59-66.
-
(2002)
Pathophysiol Haemost Thromb
, vol.32
, pp. 59-66
-
-
Lapidus, L.1
-
68
-
-
18144424789
-
Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): A prospective randomized trial
-
DOI 10.1016/j.ejvs.2004.02.029, PII S1078588405000675
-
Daskalopoulos ME, et al. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. Eur J Vasc Endovasc Surg 2005; 29: 638-650. (Pubitemid 40614350)
-
(2005)
European Journal of Vascular and Endovascular Surgery
, vol.29
, Issue.6
, pp. 638-650
-
-
Daskalopoulos, M.E.M.1
Daskalopoulou, S.S.2
Tzortzis, E.3
Sfiridis, P.4
Nikolaou, A.5
Dimitroulis, D.6
Kakissis, I.7
Liapis, C.D.8
-
69
-
-
20244379112
-
A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism
-
DOI 10.1001/archinte.165.7.733
-
Wells PS, et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med 2005; 165: 733-738. (Pubitemid 40569425)
-
(2005)
Archives of Internal Medicine
, vol.165
, Issue.7
, pp. 733-738
-
-
Wells, P.S.1
Anderson, D.R.2
Rodger, M.A.3
Forgie, M.A.4
Florack, P.5
Touchie, D.6
Morrow, B.7
Gray, L.8
O'Rourke, K.9
Wells, G.10
Kovacs, J.11
Kovacs, M.J.12
-
70
-
-
21744457102
-
Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis
-
DOI 10.1345/aph.1E677
-
Dager WE, et al. Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis. Ann Pharmacother 2005; 39: 1182-1187. (Pubitemid 40943166)
-
(2005)
Annals of Pharmacotherapy
, vol.39
, Issue.7-8
, pp. 1182-1187
-
-
Dager, W.E.1
King, J.H.2
Branch, J.M.3
Chow, S.L.4
Ferrer, R.E.5
Pak, S.6
Togioka, P.Y.7
White, R.H.8
-
71
-
-
33846023633
-
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer
-
Hull RD, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119: 1062-1072.
-
(2006)
Am J Med
, vol.119
, pp. 1062-1072
-
-
Hull, R.D.1
-
72
-
-
38449105088
-
Early discharge of patients with pulmonary embolism: A two-phase observational study
-
DOI 10.1183/09031936.00140506
-
Davies CW, et al. Early discharge of patients with pulmonary embolism: a two-phase observational study. Eur Respir J 2007; 30: 708-714. (Pubitemid 351194831)
-
(2007)
European Respiratory Journal
, vol.30
, Issue.4
, pp. 708-714
-
-
Davies, C.W.H.1
Wimperis, J.2
Green, E.S.3
Pendry, K.4
Killen, J.5
Mehdif, I.6
Tiplady, C.7
Kesteven, P.8
Rose, P.9
Oldfield, W.10
-
73
-
-
61549085322
-
A randomised open-label trial comparing long-term sub-cutaneous low-molecularweight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis
-
Romera A, et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecularweight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 2009; 37: 349-356.
-
(2009)
Eur J Vasc Endovasc Surg
, vol.37
, pp. 349-356
-
-
Romera, A.1
-
74
-
-
34249849951
-
Spontaneous recanalization in deep venous thrombosis: A prospective duplex ultrasound study
-
Puskas A, et al. Spontaneous recanalization in deep venous thrombosis: a prospective duplex ultrasound study. Int Angiol 2007; 26: 53-63. (Pubitemid 46860072)
-
(2007)
International Angiology
, vol.26
, Issue.1
, pp. 53-63
-
-
Puskas, A.1
Balogh, Z.2
Hadadi, L.3
Imre, M.4
Orban, E.5
Kosa, K.6
Brassai, Z.7
Mousa, S.A.8
-
75
-
-
34247095231
-
Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function. a comparative pharmacokinetic study
-
DOI 10.1160/TH06-09-0513
-
Mahe I, et al. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 2007; 97: 581-586. (Pubitemid 46592936)
-
(2007)
Thrombosis and Haemostasis
, vol.97
, Issue.4
, pp. 581-586
-
-
Mahe, I.1
Aghassarian, M.2
Drouet, L.3
Bal Dit-Sollier, C.4
Lacut, K.5
Heilmann, J.-J.6
Mottier, D.7
Bergmann, J.-F.8
-
76
-
-
33846461672
-
Elderly medical patients treated with prophylactic dosages of enoxaparin: Influence of renal function on anti-Xa activity level
-
DOI 10.2165/00002512-200724010-00005
-
Mahe I, et al. Elderly medical patients treated with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity level. Drugs Aging 2007; 24: 63-71. (Pubitemid 46148082)
-
(2007)
Drugs and Aging
, vol.24
, Issue.1
, pp. 63-71
-
-
Mahe, I.1
Gouin-Thibault, I.2
Drouet, L.3
Simoneau, G.4
Di Castillo, H.5
Siguret, V.6
Bergmann, J.-F.7
Pautas, E.8
-
77
-
-
0036360980
-
Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients
-
Pautas E, et al. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf 2002; 25: 725-733. (Pubitemid 34983375)
-
(2002)
Drug Safety
, vol.25
, Issue.10
, pp. 725-733
-
-
Pautas, E.1
Gouin, I.2
Bellot, O.3
Andreux, J.-P.4
Siguret, V.5
-
78
-
-
0033710044
-
Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): Anti-Xa and anti-IIa activities over 10 days
-
Siguret V, et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 2000; 84: 800-804. (Pubitemid 30946940)
-
(2000)
Thrombosis and Haemostasis
, vol.84
, Issue.5
, pp. 800-804
-
-
Siguret, V.1
Pautas, E.2
Fevrier, M.3
Wipff, C.4
Durand-Gasselin, B.5
Laurent, M.6
Andruex, J.-P.7
D'Urso, M.8
Gaussem, P.9
-
80
-
-
0036402570
-
The low molecular weight heparin, tinzaparin, in thrombosis and beyond
-
Mousa SA. The low molecular weight heparin, tinzaparin, in thrombosis and beyond. Cardiovasc Drug Rev 2002; 20: 199-216. (Pubitemid 35204768)
-
(2002)
Cardiovascular Drug Reviews
, vol.20
, Issue.3
, pp. 199-216
-
-
Mousa, S.A.1
-
81
-
-
14744305444
-
Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: Anti-cancer efficacy
-
Mousa SA, Mohamed S. Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy. Oncol Rep 2004; 12: 683-688.
-
(2004)
Oncol Rep
, vol.12
, pp. 683-688
-
-
Mousa, S.A.1
Mohamed, S.2
-
82
-
-
0037974202
-
Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: Effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects
-
Mousa SA, et al. Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects. J Clin Pharmacol 2003; 43: 727-734.
-
(2003)
J Clin Pharmacol
, vol.43
, pp. 727-734
-
-
Mousa, S.A.1
-
83
-
-
44949230063
-
Hypercoagulability in patients with haematological neoplasia: No apparent initiation by tissue factor
-
Negaard HF, et al. Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor. Thromb Haemost 2008; 99: 1040-1048.
-
(2008)
Thromb Haemost
, vol.99
, pp. 1040-1048
-
-
Negaard, H.F.1
-
84
-
-
34247866411
-
Efficacy of anticoagulants and platelet inhibitors in cancer-induced thrombosis
-
Cloonan ME, et al. Efficacy of anticoagulants and platelet inhibitors in cancer-induced thrombosis. Blood Coagul Fibrinolysis 2007; 18: 341-345.
-
(2007)
Blood Coagul Fibrinolysis
, vol.18
, pp. 341-345
-
-
Cloonan, M.E.1
-
85
-
-
0033811629
-
Comparative efficacy of different lowmolecular- weight heparins (LMWHs) and drug interactions with LMWH: Implications for management of vascular disorders
-
Mousa SA. Comparative efficacy of different lowmolecular- weight heparins (LMWHs) and drug interactions with LMWH: implications for management of vascular disorders. Semin Thromb Hemost 2000; 26 (Suppl 1): 39-46.
-
(2000)
Semin Thromb Hemost
, vol.26
, Issue.SUPPL. 1
, pp. 39-46
-
-
Mousa, S.A.1
-
86
-
-
70449505923
-
Antithrombotic efficacy of low molecular weight heparin in hypercoagulation states and cancer-associated thrombosis
-
Mousa SA, Johansen KB. Antithrombotic efficacy of low molecular weight heparin in hypercoagulation states and cancer-associated thrombosis. J Thromb Haemost 2007; 5 (Suppl 2): P-M-527.
-
(2007)
J Thromb Haemost
, vol.5
, Issue.SUPPL. 2
-
-
Mousa, S.A.1
Johansen, K.B.2
-
87
-
-
1842463681
-
Antimetastatic effect of tinzaparin, a low-molecular-weight heparin
-
Amirkhosravi A, et al. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J Thromb Haemost 2003; 1: 1972-1976.
-
(2003)
J Thromb Haemost
, vol.1
, pp. 1972-1976
-
-
Amirkhosravi, A.1
-
88
-
-
33845357884
-
Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin
-
DOI 10.1160/TH06-05-0289
-
Mousa SA, et al. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost 2006; 96: 816-821. (Pubitemid 44883824)
-
(2006)
Thrombosis and Haemostasis
, vol.96
, Issue.6
, pp. 816-821
-
-
Mousa, S.A.1
Linhardt, R.2
Francis, J.L.3
Amirkhosravi, A.4
-
89
-
-
70449468210
-
The mechanism of low molecular weight heparin (LMWH) inhibition of tumor growth
-
Abstract
-
Smiley SL, et al. The mechanism of low molecular weight heparin (LMWH) inhibition of tumor growth. J.Clin.Oncol 2006; 24: 18S (Abstract).
-
(2006)
J.Clin.Oncol
, vol.24
-
-
Smiley, S.L.1
-
90
-
-
12444330870
-
A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients
-
Daneshmand M, et al. A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin Cancer Res 2003; 9: 2457-2464. (Pubitemid 36842084)
-
(2003)
Clinical Cancer Research
, vol.9
, Issue.7
, pp. 2457-2464
-
-
Daneshmand, M.1
Parolin, D.A.E.2
Hirte, H.W.3
Major, P.4
Goss, G.5
Stewart, D.6
Batist, G.7
Miller Jr., W.H.8
Matthews, S.9
Seymour, L.10
Lorimer, I.A.J.11
-
91
-
-
20444421888
-
Therapeutic approaches in metastatic renal cell carcinoma
-
DOI 10.1111/j.1464-410X.2005.05537.x
-
Staehler M, et al. Therapeutic approaches in metastatic renal cell carcinoma. BJU Int 2005; 95: 1153-1161. (Pubitemid 40799474)
-
(2005)
BJU International
, vol.95
, Issue.8
, pp. 1153-1161
-
-
Staehler, M.1
Rohrmann, K.2
Bachmann, A.3
Zaak, D.4
Stief, C.G.5
Siebels, M.6
-
92
-
-
23944442968
-
Selective antimetastatic effect of heparins in preclinical human melanoma models is based on inhibition of migration and microvascular arrest
-
DOI 10.1007/s10585-005-3859-6
-
Bereczky B, et al. Selective antimetastatic effect of heparins in preclinical human melanoma models is based on inhibition of migration and microvascular arrest. Clin Exp Metastasis 2005; 22: 69-76. (Pubitemid 41185863)
-
(2005)
Clinical and Experimental Metastasis
, vol.22
, Issue.1
, pp. 69-76
-
-
Bereczky, B.1
Gilly, R.2
Raso, E.3
Vago, A.4
Timar, J.5
Tovari, J.6
-
93
-
-
27144534062
-
A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity
-
DOI 10.1038/sj.bjp.0706344, PII 0706344
-
Takahashi H, et al. A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity. Br J Pharmacol 2005; 146: 333-343. (Pubitemid 41486675)
-
(2005)
British Journal of Pharmacology
, vol.146
, Issue.3
, pp. 333-343
-
-
Takahashi, H.1
Ebihara, S.2
Okazaki, T.3
Asada, M.4
Sasaki, H.5
Yamaya, M.6
-
94
-
-
33846847643
-
In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas
-
Balzarotti M, et al. In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas. Oncol Res 2006; 16: 245-250.
-
(2006)
Oncol Res
, vol.16
, pp. 245-250
-
-
Balzarotti, M.1
-
95
-
-
24644478267
-
Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth
-
Kragh M, et al. Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth. Oncol Rep 2005; 14: 99-104.
-
(2005)
Oncol Rep
, vol.14
, pp. 99-104
-
-
Kragh, M.1
-
96
-
-
1242285585
-
Effect of low molecular weight heparin on intra-abdominal metastasis in a laparoscopic experimental study
-
DOI 10.1007/s00384-003-0535-7
-
Pross M, et al. Effect of low molecular weight heparin on intra-abdominal metastasis in a laparoscopic experimental study. Int J Colorectal Dis 2004; 19: 143-146. (Pubitemid 38239835)
-
(2004)
International Journal of Colorectal Disease
, vol.19
, Issue.2
, pp. 143-146
-
-
Pross, M.1
Lippert, H.2
Nestler, G.3
Kuhn, R.4
Langer, H.5
Mantke, R.6
Schulz, H.-U.7
-
97
-
-
0242380339
-
Low-molecular-weight heparin (reviparin) diminishes tumor cell adhesion and invasion in vitro, and decreases intraperitoneal growth of colonadeno-carcinoma cells in rats after laparoscopy
-
DOI 10.1016/S0049-3848(03)00296-2
-
Pross M, et al. Low-molecular-weight heparin (reviparin) diminishes tumor cell adhesion and invasion in vitro, and decreases intraperitoneal growth of colonadeno-carcinoma cells in rats after laparoscopy. Thromb Res 2003; 110: 215-220. (Pubitemid 37338296)
-
(2003)
Thrombosis Research
, vol.110
, Issue.4
, pp. 215-220
-
-
Pross, M.1
Lippert, H.2
Misselwitz, F.3
Nestler, G.4
Kruger, S.5
Langer, H.6
Halangk, W.7
Schulz, H.-U.8
-
98
-
-
70449496710
-
Anti-cancer efficacy of low molecular weight heparin in thrombosis-associated tumor growth
-
Mousa SA, Johansen KB. Anti-cancer efficacy of low molecular weight heparin in thrombosis-associated tumor growth. J Thromb Haemost 2007; 5 (Suppl 2): P-M-525.
-
(2007)
J Thromb Haemost
, vol.5
, Issue.SUPPL. 2
-
-
Mousa, S.A.1
Johansen, K.B.2
-
99
-
-
0242469234
-
Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight
-
Khorana AA, et al. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol 2003; 23: 2110-2115.
-
(2003)
Arterioscler Thromb Vasc Biol
, vol.23
, pp. 2110-2115
-
-
Khorana, A.A.1
-
100
-
-
39749083397
-
Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin
-
DOI 10.1016/j.thromres.2007.06.015, PII S0049384807002496
-
Marchetti M, et al. Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res 2008; 121: 637-645. (Pubitemid 351305285)
-
(2008)
Thrombosis Research
, vol.121
, Issue.5
, pp. 637-645
-
-
Marchetti, M.1
Vignoli, A.2
Russo, L.3
Balducci, D.4
Pagnoncelli, M.5
Barbui, T.6
Falanga, A.7
-
101
-
-
4544370585
-
Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor
-
DOI 10.1160/TH04-02-0069
-
Mousa SA, Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost 2004; 92: 627-633. (Pubitemid 39248021)
-
(2004)
Thrombosis and Haemostasis
, vol.92
, Issue.3
, pp. 627-633
-
-
Mousa, S.A.1
Mohamed, S.2
-
102
-
-
0028336966
-
165 with soluble and cell associated flk-1 receptors
-
Tessler S, et al. Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors. J Biol Chem 1994; 269: 12456-12461. (Pubitemid 24202025)
-
(1994)
Journal of Biological Chemistry
, vol.269
, Issue.17
, pp. 12456-12461
-
-
Tessler, S.1
Rockwell, P.2
Hicklin, D.3
Cohen, T.4
Levi, B.-Z.5
Witte, L.6
Lemischka, I.R.7
Neufeld, G.8
-
103
-
-
0034326271
-
Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in Vitro
-
Collen A, et al. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 2000; 60: 6196-6200. (Pubitemid 30839654)
-
(2000)
Cancer Research
, vol.60
, Issue.21
, pp. 6196-6200
-
-
Collen, A.1
Smorenburg, S.M.2
Peters, E.3
Lupu, F.4
Koolwijk, P.5
Van Noorden, C.6
Van Hinsbergh, V.W.M.7
-
104
-
-
22944447451
-
Effect of fraxiparine and heparin on experimental tumor metastasis in mice
-
Szende B, et al. Effect of Fraxiparine and heparin on experimental tumor metastasis in mice. Anticancer Res 2005; 25: 2869-2872. (Pubitemid 41044674)
-
(2005)
Anticancer Research
, vol.25
, Issue.4
, pp. 2869-2872
-
-
Szende, B.1
Paku, S.2
Racz, G.3
Kopper, L.4
-
105
-
-
33645542177
-
The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo
-
Ludwig RJ, et al. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost 2006; 95: 535-540.
-
(2006)
Thromb Haemost
, vol.95
, pp. 535-540
-
-
Ludwig, R.J.1
-
106
-
-
26444566779
-
Differential metastasis inhibition by clinically relevant levels of heparins - Correlation with selectin inhibition, not antithrombotic activity
-
Stevenson JL, et al. Differential metastasis inhibition by clinically relevant levels of heparins - correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 2005; 11: 7003-7011.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 7003-7011
-
-
Stevenson, J.L.1
-
107
-
-
33644824278
-
Non-anti-coagulant heparins: A promising approach for prevention of tumor metastasis
-
review
-
Kragh M, Loechel F. Non-anti-coagulant heparins: a promising approach for prevention of tumor metastasis (review). Int J Oncol 2005; 27: 1159-1167.
-
(2005)
Int J Oncol
, vol.27
, pp. 1159-1167
-
-
Kragh, M.1
Loechel, F.2
-
108
-
-
61449172218
-
Non-anticoagulant heparins and inhibition of cancer
-
Casu B, et al. Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb 2008; 36: 195-203.
-
(2008)
Pathophysiol Haemost Thromb
, vol.36
, pp. 195-203
-
-
Casu, B.1
-
109
-
-
34547111055
-
Affinity and kinetics of different heparins binding to P- and L-selectin
-
Simonis D, et al. Affinity and kinetics of different heparins binding to P- and L-selectin. Semin Thromb Hemost 2007; 33: 534-539.
-
(2007)
Semin Thromb Hemost
, vol.33
, pp. 534-539
-
-
Simonis, D.1
-
110
-
-
36049013035
-
Heparin attenuates metastasis mainly due to inhibition of P- And L-selectin, but non-anticoagulant heparins can have additional effects
-
Stevenson JL, et al. Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects. Thromb Res 2007; 120 (Suppl 2): S107-S111.
-
(2007)
Thromb Res
, vol.120
, Issue.SUPPL. 2
-
-
Stevenson, J.L.1
-
111
-
-
57349172005
-
Melanoma cell adhesion can be blocked by heparin in vitro: Suggestion of VLA-4 as a novel target for antimetastatic approaches
-
Fritzsche J, et al. Melanoma cell adhesion can be blocked by heparin in vitro: suggestion of VLA-4 as a novel target for antimetastatic approaches. Thromb Haemost 2008; 100: 1166-1175.
-
(2008)
Thromb Haemost
, vol.100
, pp. 1166-1175
-
-
Fritzsche, J.1
-
112
-
-
16544390675
-
Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis
-
Ludwig RJ, et al. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res 2004; 64: 2743-2750.
-
(2004)
Cancer Res
, vol.64
, pp. 2743-2750
-
-
Ludwig, R.J.1
-
113
-
-
34250634775
-
Parnaparin, a low-molecular-weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood
-
DOI 10.1160/TH06-12-0680
-
Maugeri N, et al. Parnaparin, a low-molecularweight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood. Thromb Haemost 2007; 97: 965-973. (Pubitemid 46939210)
-
(2007)
Thrombosis and Haemostasis
, vol.97
, Issue.6
, pp. 965-973
-
-
Maugeri, N.1
Di Fabio, G.2
Barbanti, M.3
De Gaetano, G.4
Donati, M.B.5
Cerletti, C.6
-
114
-
-
0035654947
-
Bemiparin and fluid flow modulate the expression, activity and release of tissue factor pathway inhibitor in human endothelial cells in vitro
-
Westmuckett AD, et al. Bemiparin and fluid flow modulate the expression, activity and release of tissue factor pathway inhibitor in human endothelial cells in vitro. Thromb Haemost 2001; 86: 1547-1554.
-
(2001)
Thromb Haemost
, vol.86
, pp. 1547-1554
-
-
Westmuckett, A.D.1
-
115
-
-
33644544424
-
Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties
-
Vignoli A, et al. Differential effect of the low-molecular- weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties. Haematologica 2006; 91: 207-214. (Pubitemid 43304140)
-
(2006)
Haematologica
, vol.91
, Issue.2
, pp. 207-214
-
-
Vignoli, A.1
Marchetti, M.2
Balducci, D.3
Barbui, T.4
Falanga, A.5
-
116
-
-
33745315219
-
Pharmacodynamic effects of low molecular weight heparin in obese subjects following subcutaneous administration of 75 IU/kg on plasma tissue factor pathway inhibitor and nitric oxide
-
Mousa SA, Johansen K. Pharmacodynamic effects of low molecular weight heparin in obese subjects following subcutaneous administration of 75 IU/kg on plasma tissue factor pathway inhibitor and nitric oxide. Int Angiol 2005; 24: 40-42. (Pubitemid 43933047)
-
(2005)
International Angiology
, vol.24
, Issue.1
, pp. 40-42
-
-
Mousa, S.A.1
Johansen, K.2
-
117
-
-
1842853070
-
Are low molecular weight heparins the same?
-
Mousa SA. Are low molecular weight heparins the same? Methods Mol Med 2004; 93: 49-59.
-
(2004)
Methods Mol Med
, vol.93
, pp. 49-59
-
-
Mousa, S.A.1
-
118
-
-
0027420108
-
Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor
-
DOI 10.1016/0049-3848(93)90233-E
-
Bara L, et al. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thromb Res 1993; 69: 443-452. (Pubitemid 23102564)
-
(1993)
Thrombosis Research
, vol.69
, Issue.5
, pp. 443-452
-
-
Bara, L.1
Bloch, M.F.2
Zitoun, D.3
Samama, M.4
Collignon, F.5
Frydman, A.6
Uzan, A.7
Bouthier, J.8
-
119
-
-
9644290832
-
Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment
-
DOI 10.1016/j.lab.2004.08.001, PII S002221430400215X
-
Brodin E, et al. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment. J Lab Clin Med 2004; 144: 246-253. (Pubitemid 39573230)
-
(2004)
Journal of Laboratory and Clinical Medicine
, vol.144
, Issue.5
, pp. 246-253
-
-
Brodin, E.1
Svensson, B.2
Paulssen, R.H.3
Nordoy, A.4
Hansen, J.-B.5
-
120
-
-
0034106458
-
A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism
-
The Bemiparin Assessment group
-
Kakkar VV, et al. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group. Thromb Haemost 2000; 83: 523-529.
-
(2000)
Thromb Haemost
, vol.83
, pp. 523-529
-
-
Kakkar, V.V.1
-
121
-
-
0028796872
-
TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin
-
Hoppensteadt DA, et al. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res 1995; 77: 175-185.
-
(1995)
Thromb Res
, vol.77
, pp. 175-185
-
-
Hoppensteadt, D.A.1
-
122
-
-
0029024359
-
Pharmacologic validation of the clinical effects of an optimized low-molecular-weight heparin-reviparin
-
Fareed J, et al. Pharmacologic validation of the clinical effects of an optimized low-molecular-weight heparin-reviparin. Semin Thromb Hemost 1995; 21: 212-227.
-
(1995)
Semin Thromb Hemost
, vol.21
, pp. 212-227
-
-
Fareed, J.1
-
123
-
-
0033399065
-
Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins
-
Bendz B, et al. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins. Br J Haematol 1999; 107: 756-762. (Pubitemid 30020146)
-
(1999)
British Journal of Haematology
, vol.107
, Issue.4
, pp. 756-762
-
-
Bendz, B.1
Hansen, J.-B.2
Andersen, T.O.3
Ostergaard, P.4
Sandset, P.M.5
-
124
-
-
0035657406
-
Thromboprophylaxis following caesarean section: A comparison of the antithrombotic properties of three low molecular weight heparins - Dalteparin, enoxaparin and tinzaparin
-
Ellison J, et al. Thromboprophylaxis following caesarean section - a comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thromb Haemost 2001; 86: 1374-1378. (Pubitemid 34007507)
-
(2001)
Thrombosis and Haemostasis
, vol.86
, Issue.6
, pp. 1374-1378
-
-
Ellison, J.1
Thomson, A.J.2
Conkie, J.A.3
McCall, F.4
Walker, I.D.5
Greer, I.A.6
-
125
-
-
47949096781
-
Cancer-related inflammation
-
Mantovani A, et al. Cancer-related inflammation. Nature 2008; 454: 436-444.
-
(2008)
Nature
, vol.454
, pp. 436-444
-
-
Mantovani, A.1
-
126
-
-
34548286862
-
Silencing of heparanase by siRNA inhibits tumor metastasis and angiogenesis of human breast cancer in vitro and in vivo
-
Zhang ZH, et al. Silencing of heparanase by siRNA inhibits tumor metastasis and angiogenesis of human breast cancer in vitro and in vivo. Cancer Biol Ther 2007; 6: 587-595.
-
(2007)
Cancer Biol Ther
, vol.6
, pp. 587-595
-
-
Zhang, Zh.1
-
127
-
-
39549115449
-
Heparin, heparan sulfate and heparanase in cancer: Remedy for metastasis?
-
Li JP. Heparin, heparan sulfate and heparanase in cancer: remedy for metastasis? Anticancer Agents Med Chem 2008; 8: 64-76.
-
(2008)
Anticancer Agents Med Chem
, vol.8
, pp. 64-76
-
-
Li, J.P.1
-
128
-
-
23844432006
-
Effect of low molecular weight heparin and different heparin molecular weight fractions on the activity of the matrix-degrading enzyme aggrecanase: Structure-function relationship
-
Mousa SA. Effect of low molecular weight heparin and different heparin molecular weight fractions on the activity of the matrix-degrading enzyme aggrecanase: structure-function relationship. J Cell Biochem 2005; 95: 95-98.
-
(2005)
J Cell Biochem
, vol.95
, pp. 95-98
-
-
Mousa, S.A.1
-
129
-
-
0036189961
-
Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: Rationale for clinical studies in humans
-
Varki NM, Varki A. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin Thromb Hemost 2002; 28: 53-66.
-
(2002)
Semin Thromb Hemost
, vol.28
, pp. 53-66
-
-
Varki, N.M.1
Varki, A.2
-
130
-
-
43149106965
-
Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: Implications for the development of generic versions of low-molecular-weight heparins
-
Jeske WP, et al. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Semin Thromb Hemost 2008; 34: 74-85.
-
(2008)
Semin Thromb Hemost
, vol.34
, pp. 74-85
-
-
Jeske, W.P.1
-
131
-
-
13444260766
-
Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: A subgroup analysis of the PREVENT trial
-
DOI 10.1001/archinte.165.3.341
-
Kucher N, et al. Efficacy and safety of fixed lowdose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med 2005; 165: 341-345. (Pubitemid 40216291)
-
(2005)
Archives of Internal Medicine
, vol.165
, Issue.3
, pp. 341-345
-
-
Kucher, N.1
Leizorovicz, A.2
Vaitkus, P.T.3
Cohen, A.T.4
Turpie, A.G.G.5
Olsson, C.-G.6
Goldhaber, S.Z.7
-
132
-
-
4644308426
-
Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
-
DOI 10.1378/chest.126.3-suppl.188S
-
Hirsh J, Raschke R. Heparin and low-molecularweight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 188S-203S. (Pubitemid 39297954)
-
(2004)
Chest
, vol.126
, Issue.3 SUPPL.
-
-
Hirsh, J.1
Raschke, R.2
-
133
-
-
33750303524
-
Bevacizumab in combination with chemotherapy: First-line treatment of patients with metastatic colorectal cancer
-
Hochster HS. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer. Semin Oncol 2006; 33 (5 Suppl 10): S8-14.
-
(2006)
Semin Oncol
, vol.33
, Issue.5 SUPPL. 10
-
-
Hochster, H.S.1
-
134
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
DOI 10.1056/NEJMoa061884
-
Sandler A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550. (Pubitemid 44917502)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.24
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
Brahmer, J.4
Schiller, J.H.5
Dowlati, A.6
Lilenbaum, R.7
Johnson, D.H.8
-
135
-
-
37349080670
-
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial
-
DOI 10.1016/S0140-6736(07)61904-7, PII S0140673607619047
-
Escudier B, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111. (Pubitemid 350296300)
-
(2007)
Lancet
, vol.370
, Issue.9605
, pp. 2103-2111
-
-
Escudier, B.1
Pluzanska, A.2
Koralewski, P.3
Ravaud, A.4
Bracarda, S.5
Szczylik, C.6
Chevreau, C.7
Filipek, M.8
Melichar, B.9
Bajetta, E.10
Gorbunova, V.11
Bay, J.-O.12
Bodrogi, I.13
Jagiello-Gruszfeld, A.14
Moore, N.15
-
136
-
-
58149377600
-
Rationale and design of PROSPECT-CONKO 004: A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy
-
Riess H, et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer 2008; 8: 361.
-
(2008)
BMC Cancer
, vol.8
, pp. 361
-
-
Riess, H.1
|